All In Biotech

Drug Trial Radar · NCT07039916

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

231

Planned (sponsor's estimate)

Start

May 27, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • IMVT-1402Drug

    • Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)

  • IMVT-1402Drug

    * Dose 2 SC QW for 12 weeks (Period 1) * Dose 2 SC QW for 14 weeks (Period 2) * Dose 2 SC QW for 52 weeks (Period 3)

  • PlaceboDrug

    • Placebo SC QW for 12 weeks (Period 1)

  • IMVT-1402Drug

    * Dose 1 SC QW for 14 weeks (Period 2) * Dose 1 SC QW for 52 weeks (Period 3)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in MG-ADL Score for Antibody-positive ParticipantsTime frame: Baseline to Week 12

Locations

93 sites in 15 countries. Site status is shown where the registry gives one.

  • Site Number - 1056

    Huntsville, Alabama · Recruiting

  • Site Number - 1041

    Mobile, Alabama · Recruiting

  • Site Number - 1017

    Phoenix, Arizona · Recruiting

  • Site Number - 1025

    Scottsdale, Arizona · Recruiting

  • Site Number - 1042

    Tucson, Arizona · Recruiting

  • Site Number - 1010

    Carlsbad, California · Withdrawn

  • Site Number - 1028

    Irvine, California · Recruiting

  • Site Number - 1023

    Los Angeles, California · Recruiting

  • Site Number - 1029

    Rancho Mirage, California · Recruiting

  • Site Number - 1004

    San Francisco, California · Recruiting

  • Site Number - 1053

    Denver, Colorado · Recruiting

  • Site Number - 1027

    Fort Collins, Colorado · Withdrawn

  • Site Number - 1001

    New Haven, Connecticut · Recruiting

  • Site Number - 1024

    Washington D.C., District of Columbia · Recruiting

  • Site Number - 1006

    Clearwater, Florida · Recruiting

  • Site Number - 1008

    Miami, Florida · Recruiting

  • Site Number - 1037

    Ormond Beach, Florida · Recruiting

  • Site Number - 1002

    Port Charlotte, Florida · Recruiting

  • Site Number - 1050

    Rockledge, Florida · Recruiting

  • Site Number - 1007

    Tampa, Florida · Recruiting

  • Site Number - 1014

    Atlanta, Georgia · Recruiting

  • Site Number - 1043

    Augusta, Georgia · Recruiting

  • Site Number - 1054

    Schaumburg, Illinois · Recruiting

  • Site Number - 1022

    Lexington, Kentucky · Recruiting

  • Site Number - 1032

    Nicholasville, Kentucky · Recruiting

  • Site Number - 1046

    New Orleans, Louisiana · Recruiting

  • Site Number - 1049

    Foxborough, Massachusetts · Recruiting

  • Site Number - 1026

    Detroit, Michigan · Recruiting

  • Site Number - 1005

    East Lansing, Michigan · Recruiting

  • Site Number - 1018

    Omaha, Nebraska · Recruiting

  • Site Number - 1019

    Totowa, New Jersey · Withdrawn

  • Site Number - 1036

    New York, New York · Recruiting

  • Site Number - 1034

    New York, New York · Withdrawn

  • Site Number - 1020

    Chapel Hill, North Carolina · Recruiting

  • Site Number - 1013

    Durham, North Carolina · Recruiting

  • Site Number - 1044

    Raleigh, North Carolina · Recruiting

  • Site Number - 1038

    Cincinnati, Ohio · Recruiting

  • Site Number - 1045

    Oklahoma City, Oklahoma · Recruiting

  • Site Number - 1011

    Yukon, Oklahoma · Withdrawn

  • Site Number - 1031

    Eugene, Oregon · Recruiting

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.